Table 2.
Summary of best response
| RECIST 1.1 | mRECIST | ||||||
|---|---|---|---|---|---|---|---|
| HAIC-LEN-PD1 | LEN-PD1 | P-value | HAIC-LEN-PD1 | LEN-PD1 | P-value | ||
| Overall Reponse | n = 103 | n = 61 | n = 103 | n = 61 | |||
| CR | 1 (0.9%) | 1 (1.6%) | 16 (15.5%) | 2 (3.3%) | |||
| PR | 65 (63.1%) | 8 (13.1%) | 63 (61.2%) | 12 (19.7%) | |||
| SD | 29 (28.2%) | 35 (57.4%) | 16 (15.5%) | 30 (49.1%) | |||
| PD | 8 (7.8%) | 17 (27.9%) | 8 (7.8%) | 17 (27.9%) | |||
| ORR | 66 (64.1%) | 9 (14.8%) | < 0.001 | 79 (76.7%) | 14 (23.0%) | < 0.001 | |
| DCR | 95 (92.2%) | 44 (72.1%) | 0.001 | 95 (92.2%) | 44 (72.1%) | 0.001 | |
| Intrahepatic Response | n = 103 | n = 61 | n = 103 | n = 61 | |||
| CR | 1 (0.9%) | 1 (1.6%) | 18 (17.5%) | 2 (3.3%) | |||
| PR | 67 (65.1%) | 9 (14.8%) | 65 (63.1%) | 13 (21.3%) | |||
| SD | 31 (30.1%) | 36 (59.0%) | 16 (15.5%) | 31 (50.8%) | |||
| PD | 4 (3.9%) | 15 (24.6%) | 4 (3.9%) | 15 (24.6%) | |||
| ORR | 68 (66.0%) | 10 (16.4%) | < 0.001 | 83 (80.6%) | 15 (24.6%) | < 0.001 | |
| DCR | 99 (96.1%) | 46 (75.4%) | < 0.001 | 99 (96.1%) | 46 (75.4%) | < 0.001 | |
CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; ORR, Objective responserate; DCR, Disease control rate